α2δ subunit of voltage-gated calcium channels

Class

gabapentinoid; structural analog of GABA that does not bind GABA-A, GABA-B, or benzodiazepine receptors and does not affect GABA uptake or degradation

Pathway

FDA label states the precise mechanism of gabapentin's analgesic and antiepileptic action is unknown; gabapentin binds the α2δ-1 auxiliary subunit of voltage-activated calcium channels, though the relationship of this binding to its clinical effects has not been established

The α2δ subunit is an auxiliary protein associated with voltage-gated calcium channels, the membrane proteins that open in response to electrical depolarization and allow calcium ions to enter neurons, triggering release of neurotransmitters. Gabapentinoids, a class of small molecules structurally related to the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), bind to the α2δ-1 subunit despite their structural resemblance to GABA; they do not act on GABA receptors or alter GABA metabolism. Binding to α2δ reduces trafficking of calcium channels to the nerve terminal membrane and dampens calcium influx during neuronal firing, which in turn decreases release of excitatory neurotransmitters such as glutamate. This reduction in excitatory signaling underlies the therapeutic rationale in conditions involving abnormal neuronal excitability, including certain seizure disorders and neuropathic pain, a type of pain arising from nerve damage rather than tissue injury, where damaged neurons often show increased calcium channel expression and heightened excitability. The precise link between α2δ binding and clinical benefit has not been fully established, and regulatory labeling for this class explicitly acknowledges that the exact mechanism of action remains undefined. Because calcium channels of this type are also expressed outside the central nervous system, modulating this target can produce effects beyond the intended therapeutic action.